

Dear

**FREEDOM OF INFORMATION – HAEMATOLOGY TREATMENT**

I write in response to your request for information in relation to haematology treatment in NHS Lothian.

Question:

1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of October 2024 and end of December 2024, or latest 3-month period available? Fedratinib (Inrebic); Momelotinib (Omjjara); Ruxolitinib (Jakavi); Hydroxycarbamide.

Answer:

<b>Patients treated, October- December 2024, NHS Lothian</b>	
<b>Medication</b>	<b>Number of patients</b>
Fedratinib (Inrebic)	7
Momelotinib (Omjjara)	7
Ruxolitinib (Jakavi)	43
Hydroxycarbamide	204

Question:

2. How many patients were treated for the following myeloproliferative diseases in the 3 months between the start of October 2024 and end of December 2024, or latest 3-month period available? Polycythaemia vera (ICD10 codes = D45, D45.0, D45X OR morphology code = 9950/3); Myelofibrosis (ICD10 codes = C944, C94.4 or D474, D47.4; OR morphology codes = 9931/3 or 9961/3); Essential thrombocythemia (ICD10 code = D473, D47.3 OR morphology code = 9962/3); Myeloproliferative Disease, Chronic (ICD10 code = D471, D47.1).

Answer:

<b>SACT Treatment, October – December 2024, NHS Lothian</b>	
<b>Medication</b>	<b>Number of patients</b>
Polycythaemia vera	57
Myelofibrosis	33
Essential thrombocythemia	78
Myeloproliferative Disease, Chronic	77 (diagnosis <i>Chronic Myeloid Leukaemia BCR-ABL +ve</i> )

## Question:

3. How many patients with Myelofibrosis (ICD10 codes = C944 or D474; OR morphology codes = 9931/3 or 9961/3) were treated with the following medicines in the 3 months between the start of October 2024 and end of December 2024, or latest 3-month period available? Ruxolitinib (Jakavi); Hydroxycarbamide.

## Answer:

I have not released numbers of 5 or fewer in the table below, as this information could lead to the identification of the individuals involved. Since we do not have their consent to release their personal data, the information is exempt under section 38 of the Freedom of Information (Scotland) Act 2002 as to provide it would breach the principles of the Data Protection Act 2018.

<b>Treatment of patients with primary Myelfibrosis, October - December 2024, NHS Lothian</b>	
<b>Medicine</b>	<b>Number of patients</b>
Ruxolitinib (Jakavi)	17
Hydroxycarbamide	≤5

## Question:

4. How many patients with Polycythaemia Vera (ICD10 codes = D45, D450, D45.0, D45X OR morphology code = 9950/3) were treated with the following medicines in the 3 months between the start of October 2024 and end of December 2024, or latest 3-month period available? Ruxolitinib (Jakavi); Hydroxycarbamide.

## Answer:

The number of patients treated with Hydroxycarbamide given in the table below includes only those treated in hospital cancer services. A number of patients are managed by shared care agreement and are not included in these figures.

<b>Treatment of patients with Polycythaemia Vera, October - December 2024, NHS Lothian</b>	
<b>Medication</b>	<b>Number of patients</b>
Ruxolitinib (Jakavi)	16
Hydroxycarbamide	30

## Question:

5. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of October 2024 and end of December 2024, or latest 3-month period available? Acalabrutinib (Calquence); Ibrutinib (Imbruvica); Pirtobrutinib (Jaypirca); Venetoclax (Venclyxto); Zanubrutinib (Brukinsa); Rituximab; Obinutuzumab (Gazyvaro).

Answer:

<b>Patients treated, July – September 2024, NHS Lothian</b>	
<b>Medication</b>	<b>Number of patients</b>
Acalabrutinib (Calquence)	31
Ibrutinib (Imbruvica)	45
Pirtobrutinib (Jaypirca)	0
Venetoclax (Venclyxto)	41
Zanubrutinib (Brukinsa)	21
Rituximab	60
Obinutuzumab (Gazyvaro)	11

Question:

6. How many patients with Chronic Lymphocytic Leukaemia OR Small B-Cell Lymphoma – ICD10 codes = C911, C91.1 OR C830, C83.0 - were treated with the following medicines in the 3 months between the start of October 2024 and end of December 2024, or latest 3-month period available? Acalabrutinib (Calquence); Ibrutinib (Imbruvica); Pirtobrutinib (Jaypirca); Venetoclax (Venclyxto); Zanubrutinib (Brukinsa); Obinutuzumab (Gazyvaro); Rituximab; Bendamustine; Chlorambucil; Fludarabine; Cyclophosphamide.

Answer:

I have not released numbers of 5 or fewer in the table below, as this information could lead to the identification of the individuals involved. Since we do not have their consent to release their personal data, the information is exempt under section 38 of the Freedom of Information (Scotland) Act 2002 as to provide it would breach the principles of the Data Protection Act 2018.

<b>Treatment of patients with Chronic Lymphocytic Leukaemia or Small B-Cell Lymphoma, October - December 2024, NHS Lothian</b>	
<b>Medication</b>	<b>Number of patients</b>
Acalabrutinib (Calquence)	30
Ibrutinib (Imbruvica)	28
Pirtobrutinib (Jaypirca)	0
Venetoclax (Venclyxto)	28
Zanubrutinib (Brukinsa)	≤5
Obinutuzumab (Gazyvaro)	9
Rituximab	≤5
Bendamustine	0
Chlorambucil	≤5
Fludarabine	0
Cyclophosphamide	≤5

Question:

7. How many patients with Chronic Lymphocytic Leukaemia OR Small B-Cell Lymphoma were treated with the following medicines as monotherapy, or in combination, in the 3 months between the start of October 2024 and end of December 2024, or latest 3-month period available? Ibrutinib + venetoclax; Obinutuzumab + venetoclax; Zanubrutinib monotherapy / maintenance; Ibrutinib monotherapy / maintenance; Venetoclax monotherapy; Venetoclax + rituximab.

Answer:

I have not released numbers of 5 or fewer in the table below, as this information could lead to the identification of the individuals involved. Since we do not have their consent to release their personal data, the information is exempt under section 38 of the Freedom of Information (Scotland) Act 2002 as to provide it would breach the principles of the Data Protection Act 2018.

<b>Treatment of patients with Chronic Lymphocytic Leukaemia or Small B-Cell Lymphoma, October - December 2024, NHS Lothian</b>	
<b>Medication</b>	<b>Number of patients</b>
Ibrutinib + venetoclax	≤5
Obinutuzumab + venetoclax	9
Zanubrutinib monotherapy / maintenance	≤5
Ibrutinib monotherapy / maintenance	26
Venetoclax monotherapy	13
Venetoclax + rituximab	≤5

Question:

8. How many patients with Mantle Cell Lymphoma (ICD-10 code = C83.1) were treated with the following medicines, in the 3 months between the start of October 2024 and end of December 2024, or latest 3-month period available? Acalabrutinib; Ibrutinib; Zanubrutinib.

Answer:

I have not released numbers of 5 or fewer in the table below, as this information could lead to the identification of the individuals involved. Since we do not have their consent to release their personal data, the information is exempt under section 38 of the Freedom of Information (Scotland) Act 2002 as to provide it would breach the principles of the Data Protection Act 2018.

<b>Treatment of patients with Mantle Cell Lymphoma, October - December 2024, NHS Lothian</b>	
<b>Medicine</b>	<b>Number of patients treated</b>
Acalabrutinib	≤5
Ibrutinib	≤5
Zanubrutinib	0

## Question:

9. How many patients with Acute Myeloid Leukaemia – ICD10 code = C920 - were treated with the following medicines in the 3 months between the start of October 2024 and end of December 2024, or latest 3-month period available? Azacitidine; Cytarabine; Venetoclax (Venclyxto).

## Answer:

<b>Treatment of patients with Acute Myeloid Leukaemia, October - December 2024, NHS Lothian</b>	
<b>Medication</b>	<b>Number of patients</b>
Azacitidine	17
Cytarabine	10
Venetoclax (Venclyxto)	13

## Question:

10. How many patients with Acute Myeloid Leukaemia were treated with the following medicines in combination, in the 3 months between the start of October 2024 and end of December 2024, or latest 3-month period available? Venetoclax + Azacitidine (with or without posaconazole); Venetoclax + Cytarabine (inc. V + LDAC, V + ARAC, V+ ARA-C)

## Answer:

<b>Treatment of patients with Acute Myeloid Leukaemia, October - December 2024, NHS Lothian</b>	
<b>Medication</b>	<b>Number of patients</b>
Venetoclax + Azacitidine (with or without posaconazole)	13
Venetoclax + Cytarabine (inc. V + LDAC, V + ARAC, V+ ARA-C)	0

I hope the information provided helps with your request.

If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at <https://www.foi.scot/appeal>. If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.

If you require a review of our decision to be carried out, please write to the reviewer at the address at the top of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: <https://org.nhslothian.scot/FOI>

Yours sincerely

**ALISON MACDONALD**  
**Executive Director of Nursing Midwifery and AHPs**  
Cc: Chief Executive